Biotech Values

[DewDiligence]

AVRO—>TECX at tomorrow’s open—pursuant to previously announced reverse-merger:

https://investors.tectonictx.com/news-releases/news-release-details/tectonic-therapeutic-announces-closing-merger-avrobio-well

Concurrent with the merger, Tectonic completed a $130.7 million private placement with a syndicate of new and existing investors, including a major mutual fund, TAS Partners, 5AM Ventures, EcoR1 Capital, Polaris Partners, certain funds and accounts advised by Farallon Capital Management, Vida Ventures, the PagsGroup, and other undisclosed investors. Following these transactions, Tectonic’s cash, cash equivalents and investments of approximately $181 million at close, before payment of final transaction-related expenses, is expected to fund current operational plans into mid-2027.

See the highlighted portion of #msg-173735605 for info on what Tectonic does.